Loading company
DNA X, Inc.
SONM · Nasdaq · ·
Next earnings: October 30, 2026
$4.33+0.5%Sep 29 close
- 1M
- +25.1%
- 6M
- +10.5%
- 1Y
- -60.2%
- 5Y
- -99.1%
SONM · Nasdaq · ·
Next earnings: October 30, 2026
$4.33+0.5%Sep 29 close
DNA X, Inc. is scheduled to report next on October 30, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending September 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2025 | 3 months toSep 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $16.2M | $15M | +7.94% |
| Profit | -$1.2M | -$7.5M | +83.32% |
| Profit per share | -$0.92 | -$0.65 | -41.54% |
| Free Cash Flow | -$4.5M | -$363K | -1,144.35% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Having successfully completed a strategic exit from our legacy business, management has made a deterministic decision to reallocate our resources into the high-growth, high-margin decentralized AI and crypto trading sectors,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
DNA X operates an advanced artificial intelligence platform that automates complex workflows and decision-making using state-of-the-art AI models.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from DNA X, Inc.’s Item 2.02 8-K filed May 20, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
DNA X, Inc. has no earnings call transcript available.